Menveo is novel because it both covers four (A,C,W-135,Y) of the five major meningococcal serogroups and is immunogenic and safe when given as a four-dose schedule starting at 2 months of age 8.
LONDON, GREATER LONDON, UNITED KINGDOM, March 10, 2025 /EINPresswire / -- How Has the Menveo Market Performed in Recent Years, and What Does Its Future Hold? The Menveo market has experienced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback